Drugs / therapeutic immune globulin
therapeutic immune globulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00806767 | Mar 2007 → May 2011 | leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloproliferative neoplasm +1 | Institut Paoli-Calmettes | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00002809 Background | Aug 1996 → Dec 2003 | leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease | Temple University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | therapeutic immune globulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00806767 ↗ |
| Modality | Protein / enzyme biologic | “therapeutic immune globulin” NCT00806767 ↗ |